T he Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in 2012 from a patient with fatal pneumonia in Jeddah, Saudi Arabia. 1 From 2012 through July 2014, at least 834 laboratory-confirmed cases of MERS-CoV infection associated mostly with respiratory tract illness were reported to the World Health Organization; of these cases, 288 were fatal. Known cases have been directly or indirectly linked to countries in the Arabian peninsula. 2 The epidemiologic features of MERS remain poorly defined. Studies that have modeled the reproductive rate of MERS-CoV in humans have been based on notified, clinically apparent cases and auxiliary measurements, such as the viral evolutionary rate. 3, 4 However, these studies have emphasized the need to reevaluate estimates of reproductive rates through laboratory-based investigations of the actual rate of transmission, including silent and subclinical infections. Any unnoticed transmission of the virus in the population could explain why newly identified index cases often cannot be linked to zoonotic exposure. However, to date, the lack of serologic tools has hindered in-depth investigation of rates of secondary transmission.
To determine the rate of silent or subclinical secondary infection after exposure to primary cases of MERS-CoV infection, we performed a cross-sectional laboratory investigation of 280 household contacts of 26 index patients, with additional follow-up serologic analysis in 44 contacts. All the contacts were tested for the presence and quantity of viral RNA in throat-swab samples and for antibodies in blood with the use of a staged serologic algorithm that is based on results from enzyme-linked immunosorbent assays (ELISAs), immunofluorescence assays, and plaque-reduction neutralization testing (PRNT).
Me thods

Patients
Household contact clusters were associated with the 26 index patients in whom MERS-CoV infection was diagnosed from June 4, 2013, to November 5, 2013, with one cluster per index patient. The median date on which clusters were sampled was September 8, 2013 . Diagnoses in index patients were based on hospitalization with bilateral pneumonia and detection of MERS-CoV in respiratory samples on reverse-transcriptase-polymerase chain reaction (RT-PCR). All household contacts of index patients (who were defined as persons living in the same house, regardless of the degree of relation to the index patient) were obliged to participate in the investigation per decree of the Ministry of Health as part of a public health response. Clusters occurred in Riyadh (16 clusters), Eastern Province (3), Al-Hasa (2), Hafr Al-Batin (2), Jubail (2) , and Jeddah (1).
MERS-CoV RT-PCR Assay
We performed RT-PCR assays on RNA that was extracted from upper respiratory tract swabs, with screening for the MERS-CoV genomic region upstream of the envelope gene (upE) and within open reading frame (ORF) 1a, as described previously. 5, 6 Confirmation of upE results by ORF1a detection involved the reextraction of RNA from the original samples.
Full-Virus Immunofluorescence Assay
Immunofluorescence assays were performed with slides carrying Vero cells infected with full MERS-CoV, as described previously, 6 and were manufactured into a homogeneous reagent format by an in vitro diagnostics company for improved lot-to-lot consistency (MERS IIFT, Euroimmun). The serum predilution was 1:100.
Recombinant Immunofluorescence Assay
We performed recombinant immunofluorescence assays to determine the specific reactivity against recombinant spike proteins in VeroB4 cells, as described previously. 6 The screening dilution was 1:40. Because the CoV spike protein constitutes the most specific and immunogenic antigen in CoV antibody assays, 7 open reading frames for full spike proteins were cloned from human coronaviruses (HCoV) HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, as well as for the severe acute respiratory syndrome coronavirus (SARS-CoV). 6, 8 Cells for all slides were seeded on chamber slides and transfected in parallel with equal amounts of the respective expression plasmids. 6, 8 To compare titers for MERS-CoV with those for different HCoVs, immunofluorescence assays were performed by the same staff member on the same day. Control serum samples for HCoV recombinant immunofluorescence assays were obtained from patients with recent RT-PCR-confirmed HCoV-229E, HCoV-NL63, HCoV-OC43, or HCoV-HKU1 infection, as seen in routine diagnostic testing. The methods for obtaining control serum samples for testing for the presence of MERS-CoV and SARS-CoV have been described previously. 6, [8] [9] [10] 
IgM Immunofluorescence Assay
Immunofluorescence assay was used to determine the presence of IgM antibodies. All serum samples were depleted of IgG antibodies with the use of Eurosorb reagent (Euroimmun), according to the protocol. The screening dilution was 1:40. Secondary detection was performed with the use of fluorescein isothiocyanate (FITC)-conjugated antihuman IgM antibodies.
Recombinant ELISA
A recombinant ELISA assay was based on soluble MERS-CoV spike protein S1 domain expressed in HEK-293T cells. 11 This test was developed with the use of samples obtained from small groups of humans and camels in preliminary studies. 7, 12 The dilution of human serum samples in this test was 1:100. Additional technical details are provided in Section 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Neutralization Testing
PRNT was performed as described previously. 8 The entry dilution in log 2 -dilution series was 1:10. Serum dilutions causing plaque reductions of 90% (PRNT 90 ) and 50% (PRNT 50 ) were recorded as titers.
Diagnostic Algorithm to Identify Secondary Transmission
We used the above-mentioned RT-PCR method to screen for MERS-CoV in throat swabs. Serum samples were initially screened for antibodies by means of an ELISA. Supportive serologic testing was performed in two stages. Stage 1 seropositivity was defined as reactivity on both an ELISA and a recombinant immunofluorescence assay. Stage 2 seropositivity was defined as stage 1 seropositivity plus reactivity on PRNT. Patients who had dual positive RT-PCR results or positive stage 2 serologic results were determined to have probable cases of secondary transmission. A flow chart summarizing the diagnostic algorithm and overall study outcome is provided in Figure 1 .
R esult s
Study Population
The household clusters we studied included a mean of 11 contacts (range, 2 to 21). The median age of the 26 index patients was 55 years (range, 2 to 83; mean, 54.6); 17 of the patients were male. Of these patients, 24 had coexisting illnesses, 24 required treatment in an intensive care unit, and 18 died. Index patients had stayed at home with symptoms before hospital admission for an average of 6 days (range, 0 to 21). The median age of the 280 household contacts was 29 years (range, 2 to 77; mean, 30.7); 48% of these contacts were female. A total of 59 household contacts were 16 years of age or younger.
The median interval from the onset of symptoms in index patients to the collection of the latest blood sample from household contacts was 17.5 days (range, 5 to 216; mean, 34.4). Information with respect to coexisting illnesses was recorded for 178 household contacts; of these contacts, 12% had coexisting illnesses (Table S1 in the Supplementary Appendix).
Laboratory Testing
Throat swabs from all household contacts were initially tested for MERS-CoV RNA by means of RT-PCR. Of the 280 contacts, 7 (2%) who lived in three clusters had dual positive results on RT-PCR (Fig. 1A) . Virus RNA levels in swabs obtained from these contacts ranged from fewer than 500 copies to 80,000 copies per swab sample, with a median level of 2700 copies per sample (Table 1) . Only 1 contact with positive results on RT-PCR had mild symptoms at the time of sampling, and 2 contacts had had contact with camels, which have been identified as possible reservoirs for MERS-CoV. 12 Serologic testing was based on a staged algorithm (Fig. 1B) . The algorithm was established after comparative testing of primary serum samples from all 280 household contacts, with one sample per person (Section 3 in the Supplementary Appendix). These combined studies suggested that a recombinant immunofluorescence assay would be an appropriate first-stage diagnostic test for seropositivity for ELISA-based screening results. A total of 6 household contacts had positive ELISA results and positive results on recombinant immunofluorescence assay, fulfilling the definition of stage 1 seropositivity. These household contacts included none of those with positive results on RT-PCR. Serum from the RT-PCRpositive contacts had been obtained 4 to 14 days after the onset of symptoms in the index patients, which suggested that these contacts were still in the period before seroconversion.
We asked all the household contacts for permission to obtain a second blood sample after 2 to 6 months for additional testing. Only 44 contacts in nine clusters agreed to provide a second sample. Of these contacts, 5 had positive results on ELISA; of these 5 contacts, 2 were seropositive on recombinant immunofluorescence assays (stage 1 seropositivity) (Fig. 1C) . One of these 2 contacts had stage 1 seropositivity on the basis of his first serum sample, and the other (Contact 180) underwent seroconversion sometime between the first and second serum sample (Table S6 in the Supplementary Appendix).
Stage 2 seropositivity was tested on the basis of the above-mentioned PRNT cutoffs (PRNT 90 and PRNT 50 ). PRNT 90 titers were positive in an index patient (who was used as a control in the analysis of household contacts) and in samples obtained from 2 of 7 household contacts with stage 1 seropositivity. Three additional samples had positive PRNT 50 titers ( Table 2 ). To correlate serum neutralizing activities with specific antibody titers, we performed differential recombinant immunofluorescence assays against all common HCoVs in all samples with confirmed stage 1 seropositivity ( PRNT 90 , we chose PRNT 50 as a criterion to define stage 2 seropositivity in our diagnostic algorithm. Application of this criterion resulted in the identification of 5 household contacts with stage 2 seropositivity.
Since it is unknown whether the development of neutralizing antibodies as measured on PRNT can lag behind the development of reactivity on ELISA and immunofluorescence assay, we evaluated IgM antibodies as an additional potential indicator of recent infection. However, IgM titers were detected in serum samples that had positive PRNT 90 titers but not in samples with isolated PRNT 50 titers, which suggests that testing for IgM antibodies in an immunofluorescence assay-based format provides low sensitivity overall (Table 2) . Table 3 summarizes the final study results, including the results of testing of second serum samples when they were available.
Discussion
We report the results of a targeted investigation of silent and mild infections in the 280 household contacts of 26 index patients in whom MERS-CoV infection had been confirmed on RT-PCR assay with corroborating clinical findings. Seven household contacts carried MERS-CoV in their upper respiratory tract, as shown on RT-PCR assays. Pharyngeal RNA concentrations were low in most contacts, a finding that matches observations in a study on SARS in Taiwan in which asymptomatic or mildly symptomatic health care workers were shown to carry low pharyngeal levels of viral RNA after exposure to patients infected with SARS-CoV. 13 Our findings suggest that young persons without coexisting illnesses may be able to carry low levels of MERS-CoV RNA without obvious symptoms. * Secondary infection was defined as dual positivity on RT-PCR assay or stage 2 seropositivity. ELISA denotes enzyme-linked immunosorbent assay, F female, IFA immunofluorescence assay, M male, and PRNT plaque-reduction neutralization testing. † The latency period was the number of days between the onset of symptoms in the index patient and sampling of the household contact. ‡ The result was based on positive outcome of two independent RT-PCR assays in the upE and ORF1a target genes after reextraction from the original sample. The approximate concentration is based on the upE target gene assay. § This sample was tested in a local laboratory by means of RT-PCR assays in the upE and ORF1a target genes without recording of values for the threshold cycle (RNA concentration unknown). The original sample was not retrievable. ¶ This symptom was recorded on the day of sampling. Respiratory failure and death occurred in this contact soon after testing. ‖ For this household contact, laboratory results are based on a second follow-up serum sample.
Asymptomatic, RT-PCR-positive health care workers were identified in a recent outbreak of MERS in Jeddah.
However, positive RT-PCR findings in persons with subclinical infection who are tested soon after exposure should be complemented by serologic analysis. In three earlier cross-sectional serologic studies, none of the 3024 participants showed evidence of previous infection with MERS-CoV. 1, 14, 15 In our study, the detection of antibodies was most likely due to our focus on household contacts of index patients. Differences in assay sensitivity may play an additional role. Our staged serologic algorithm is based on earlier experience with current assays or their technical precursors 6, 8, 12, 14, [16] [17] [18] [19] [20] and was developed as much as possible by a comparison of methods in the study samples available. Although validation of this algorithm will be necessary, our results suggest that ELISA is an appropriate screening assay and that recombinant immunofluorescence assay is an appropriate first-stage confirmatory test, owing to its higher specificity without an apparent substantial lack of sensitivity. Differential serologic testing by means of recombinant immunofluorescence assay cannot be used to rule out MERS-CoV infection, since anti-MERS-CoV titers did not always predominate in probable cases of secondary transmission. It is unknown whether MERS-CoV infection may cause a boost in preexisting titers against related HCoVs acquired earlier in life, such as is seen with many other infectious diseases. There are conserved regions between S proteins in MERS-CoV and those in various HCoVs that might explain the existence of cross-reactive serum antibodies (Fig. S2 in the Supplementary Appendix). Testing for stage 2 seropositivity will therefore have to rely on PRNT as long as no better information regarding antibody cross-reactivity between MERS and HCoVs is available. We consider PRNT to be the most specific test because of its reliance on functionality of measured antibodies, but we cannot rule out cross-reactivity for results obtained.
In our study population, we encountered household contacts in whom serum neutralizing activity became apparent only when we used a 50% reduction in the test virus as a more sensitive diagnostic criterion than 90% reduction. This suggests that neutralizing antibodies are produced at low levels and are potentially short-lived after mild or asymptomatic infection, which puts the predictive value of cross-sectional serologic studies in perspective if such studies are not specifically targeted at persons with recent exposure. An important limitation of our study was the low rate of household contacts from whom we could obtain a second blood sample. Although the first serologic investigation was obligatory, the participation in follow-up investigations was voluntary. The sentiment in Saudi Arabia at the time that we conducted the study was dominated by stigmatization of patients with MERS and discrimination against affected families. There was a widespread belief that medical care facilities act as sources of infection, triggered by media reports focusing on hospital outbreaks, such as that in Al-Hasa. 21 For the combination of these reasons, household contacts would widely refuse to participate in any research activity connected with MERS.
Because of the limited number of follow-up samples and the variable timing of contactcluster investigations, the timing of serologic testing after the onset of symptoms in the index patients might have influenced the diagnostic usefulness of the various tests that we used. Positive RT-PCR findings in our study were identified only during the first 14 days after exposure, whereas stage 2 seropositivity was identified only 13 days or more after exposure (Table 1) . This matches expected patterns of laboratory results when infections are acquired around the time of or shortly after exposure (defined as the time of symptom onset in index patients). In particular, the timing of the first antibody results for stage 2 seropositivity matches the typical * Percentages may not sum to the overall total in a category because of rounding. † For household contacts who provided serum samples more than 3 weeks after exposure, the indicated test results are based on second samples if they were available. ‡ One cluster included a contact with positive results on RT-PCR and another with positive serologic results.
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n engl j med 371;9 nejm.org august 28, 2014 835 timing for the development of an IgG response. If we had evaluated only household contacts who had provided serum samples 13 days or more after exposure and considered only serologic results, we would have identified cases of probable transmission in 5 of 172 contacts (3%; 95% confidence interval [CI], 1 to 7) in 4 of 17 clusters (24%). These data from limited testing are consistent with the overall study results on the basis of RT-PCR and serologic analysis (i.e., rates of secondary infection of 4% [95% CI, 2 to 7] among household contacts, in 23% of the clusters). Therefore, although RT-PCR testing may have compensated for a lack of serologic followup in household contacts who provided serum samples only during the first 2 weeks after exposure, we cannot determine whether we may have missed contacts who had delayed seroconversion. We also could not evaluate possible common sources of exposure for index patients and their household contacts.
Finally, it is relevant to note that in the whole study, we identified only 12 household contacts who may have been infected by 26 index cases. Although rates of secondary transmission may be higher in other situations, such as nosocomial outbreaks or social circumstances in which there may be a more closed or intimate environment, these data may inform approaches to estimating the epidemiologic reach of MERS-CoV in humans. 3 We thank all the staff members at the Saudi Arabian Ministry of Health. To provide an impression of the signal-to-noise ratio in patients investigated in the present study, Figure S1 shows the OD ratio values obtained with all primary serum samples except 6 samples from the first blood samplings, as well as all 44 follow-up serum samples.
Supplementary Data
Additional information on contact subjects
Information on underlying diseases was recorded on the basis of a standardized questionnaire for 178 contact cases (Supplementary Table S1 ).
Auxiliary analyses to reach a serological strategy for contact testing
The lack of reference samples to validate different serological methods requires a pragmatic approach to the interpretation of serological results. The following text describes essential analyses and considerations behind our choice of criteria for defining stages of laboratory evidence of infection.
IFA specificity and choice of IFA method for additional testing
Initial testing of 280 sera (first bleedings) yielded 19 sera reactive by ELISA and six sera reactive by rIFA. While the six rIFA-reactive samples were congruent with 19 samples reactive in ELISA, vIFA identified three additional reactive sera which where neither overlapping ELISA results nor reactive by NT or IgM. Similar results had been obtained earlier using vIFA during contact tracing studies in Germany and a cross-sectional serosurvey in Jeddah/KSA (Table S3 1,2 ). These were interpreted as cross-reactive or nonspecific titers in earlier studies. To determine titers against common HCoV, differential rIFA was used under a protocol that involves screening of serum at dilutions 1:100 and 1:1000 instead of full Log2 titration. The results for those three sera that tested positive only by vIFA are shown in Table S2 , suggesting the presence of dominant titers against common HCoVs other than MERS-CoV in these sera. For reference we summarize the results from our earlier studies in Table S3 . Overall these results document the limited specificity of vIFA. rIFA was therefore used for further studies.
Additional testing
To decide whether ELISA results should be tested by rIFA we relied on the assumption that true positive cases should have developed antibodies following recent contact with an index case. We therefore determined whether time since exposure correlated with rates of antibody results in contacts ( Table S4) 
Sensitivity of ELISA and rIFA
Because 14 sera reacted by ELISA but not by rIFA (13 in the first sampling of 280 subjects, 1 in the second sampling of 44 subjects), we determined whether these samples had concomitant titers against common HCoV. Differential rIFA was therefore done like above. The results for all 14 sera as shown in Table S5 confirm the presence of titers against common HCoVs other than MERS-CoV in all sera. However, further studies will be necessary to determine whether antibodies against HCoV cross-react with MERSCoV.
In spite this analysis suggested the excess of ELISA-positive samples to be a result of lack of specificity in ELISA rather than superior sensitivity over rIFA, it was difficult to compare sensitivity directly because this would require serum panels taken sequentially during seroconversion on different patients. For the purpose of this study, we could only 
Technical considerations regarding neutralization assay format
Virus neutralization test (NT) is based on co-incubation of patient serum with a seed dose of virus in the range of 50 to 100 infectious units (plaque forming units) followed by subsequent infection in cell culture. In the context of this study we were interested to apply a highly sensitive version of NT. Sensitivity can be increased by reducing the virus seed dose. However, seed dose should not be decreased below 50 infectious units to avoid variation due to poisson distribution effects. We therefore chose a version of NT which relies on plaque assay cell culture read out wherein the cell monolayers used to detect remaining infectious virus after serum co-incubation are overlaid with a diffusion barrier medium that reveals infection events caused by individual infectious virus particles contained in the seed dose. This assay format enabled us to determine the antibody titer that was capable of reducing the infectious virus seed dose by 50% and by 90%, instead of 100% reduction as in a normal NT. The 50% and 90% plaque reduction neutralization titers are referenced as PRNT50 and PRNT90. As the entry dilution in these titrations was 1:10, titers equal or greater than 1:20 were counted as significant. Results of comparative testing are summarized in the main text, Table 2 .
Supplementary Figures
Figure S1
Figure S1. ELISA Cutoff in relation to actual OD ratios in 274 sera from contact subjects (first collection) and all 44 sera in the second collection. Sere were pre-diluted 1:100. Optical densities (OD) were measured at 450 nm. Ratios were determined by dividing individual OD values with a calibrator serum used in all rELISA tests. Tables   5.1 Table S1 . Comorbidities in 178 of 280 studied subjects 6 References
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